newsfilter
← Latest News
GlobeNewswire·

Bionano Announces Hiring of Chief Scientific Officer

BNGO
  • Bionano Genomics appointed Alex Hastie, Ph.D., as Chief Scientific Officer effective July 20, 2026.
  • Dr. Hastie will lead the company's global scientific strategy, innovation roadmap, & research initiatives to advance genome analysis technologies & develop a clinical applications strategy.
  • He returns to Bionano after more than 14 years as a foundational figure in developing the company's optical genome mapping (OGM) core technologies.
  • His tenure prior to this role included work on genomic testing in oncology for diagnosis & therapy selection.
  • Dr. Al Luderer, chairman & interim CEO, cited Dr. Hastie's deep institutional knowledge & scientific vision as key assets for leading the scientific organization.
  • Dr. Alexander Hoischen of Radboud University Medical Center stated Dr. Hastie is essential for guiding OGM robustness, scalability, & expanding collaborative research.
  • Dr. Ying Zou of Johns Hopkins School of Medicine expressed excitement to strengthen collaboration on cancer biology insights & OGM applications in hematologic & solid tumor malignancies.
  • Dr. Rashmi Kanagal-Shamanna of MD Anderson Cancer Center highlighted Dr. Hastie's expertise as a tremendous asset for advancing OGM applications.
  • Dr. Wahab A. Khan of Dartmouth Hitchcock Medical Center noted Dr. Hastie's vision will drive important advances in optical genome mapping.
  • Dr. Hastie stated the company is entering a season of reinvention to provide novel & robust solutions for clinical genomic research.
  • As CSO, Dr. Hastie will focus on strengthening global clinical & research collaborations, expanding evidence generation, & accelerating OGM translation into broader clinical research uses.
  • Bionano offers OGM solutions, platform-agnostic analysis software, & nucleic acid extraction using proprietary isotachophoresis (ITP) technology.
  • The company's products are designated for research use only & not for diagnostic procedures.
  • The press release includes forward-looking statements regarding market adoption, financial results, & the company's ability to obtain financing or reach profitability.
  • Investor relations contact is Webb Campbell at Gilmartin Group.